Celltrion Inc
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 48
- Registration Number
- NCT05363384
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
Phase 3
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: CT-P63 and CT-P66 / Placebo
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Celltrion
- Registration Number
- NCT05224856
A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects
Phase 1
- Conditions
- Healthy Subjects
- Interventions
- Biological: CT-P47Biological: EU-approved RoActemra,
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 300
- Registration Number
- NCT05188378
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 24
- Registration Number
- NCT05017168
- Locations
- 🇵🇱
Biokinetica S.A, Józefów, Poland
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Health, Subjective
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 41
- Registration Number
- NCT05009368
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Health, Subjective
- Interventions
- Drug: CTL0801 (Azilsartan)Drug: CTL0802 (Rosuvastatin)Drug: CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 37
- Registration Number
- NCT05002244
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis
Phase 3
Completed
- Conditions
- Postmenopausal Women With Osteoporosis
- Interventions
- Biological: CT-P41Biological: US-licensed Prolia
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 479
- Registration Number
- NCT04757376
- Locations
- 🇵🇱
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Mazowieckie, Poland
🇪🇪East Tallinn Central Hospital-Ravi 18, Tallinn, Harjumaa, Estonia
🇱🇻Health Center 4-117 K. Barona Str, Riga, Latvia
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
Phase 3
Completed
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Biological: CT-P42Biological: Eylea
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 348
- Registration Number
- NCT04739306
- Locations
- 🇸🇰
II. Ocna klinika SZU, F.D.Roosevelt Hospital, Banska Bystrica, Slovakia
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: CT-P43Biological: Stelara
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 509
- Registration Number
- NCT04673786
- Locations
- 🇪🇪
Clinical Research Centre, Tartu, Tartu Country, Estonia, Estonia
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
Phase 2
Completed
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: CT-P59Biological: Placebo
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 1642
- Registration Number
- NCT04602000
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath